A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: PE

  • Acute DVT/ PE and Airline Travel

    Stephan Moll, MD writes… Can the patient with acute DVT or PE safely fly, or should he/she wait for a few weeks before embarking on airline travel?  It appears safe to fly early: There is no evidence that flying early after the diagnosis of VTE leads to an increased risk of recurrent VTE or embolization…

  • MTHFR and Homocysteine: Information Handout for Patients

    Stephan Moll, MD writes… A plain language summary for patients and interested public about homocysteine and the MTHFR mutations and their relevance in respect to thrombosis was  published today in the journal Circulation (link here). Reference:  Moll S, Varga EA.  Homocysteine and MTHFR Mutations. Circulation. 2015;132:e6-e.

  • Two Things Physicians Should Avoid

    Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1].

  • Apixaban (Eliquis) FDA-Approval for DVT and PE Treatment

    Stephan Moll, MD writes…  Apixaban (Eliquis®) was approved by the FDA this week (Aug 21, 2014) for the treatment of DVT and PE.  The approval covers (a) acute DVT/PE management and (b) prevention of recurrent DVT/PE.

  • How Long is the Post-Partum Period in Respect to Thrombosis Risk?

    Stephan Moll, MD writes… A recent NEJM study (ref 1) examined whether the risk for thrombosis in women persists beyond the first 6 weeks after delivery.  It found that an increased risk persists for at least 3 months after delivery, although the absolute risk was low after the first 6 weeks.  This is of clinical…

  • NEJM Publication: Edoxaban for VTE Treatment

    Stephan Moll, MD writes…  Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

  • International Coagulation Meeting (ISTH 2013): Highlights

    Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

  • New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE

    Stephan Moll, MD writes…   An important study (AMPLIFY trial) was published today in the New England Journal of Medicine [ref 1]: In a large study of 5395 patients with acute DVT or PE, Eliquis (apixaban) was as effective as warfarin and caused less major bleeding.